Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) has emerged as a significant public health problem. Besides the liver, NAFLD is also associated with increased cardiovascular and overall morbidity and mortality. NAFLD warrants intensive research, because no treatment has been established as yet. This may be partly attributed to the fact that the majority of the relative clinical trials have a monotherapeutic direction. However, the multifactorial pathogenesis of NAFLD may probably direct clinical trials to a combined therapeutic approach. The aim of this review is to provide a description of the multifactorial pathogenesis of NAFLD and type II diabetes mellitus-NAFLD interplay, and to summarize the therapeutic trials focusing on the combined NAFLD treatment, providing a link between the multiple-hit pathogenesis and the multimodal treatment of NAFLD patients. A diabetes-like therapeutic approach for NAFLD is finally proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“NAFLD is regarded as the hepatic component of IR syndrome.(27,28) Under the term metabolic or IR syndrome are clustered pathologic components that share IR as a common pathogenetic mechanism, including T2DM, obesity, dyslipidemia, hypertension, polycystic ovary syndrome, and endothelial dysfunction, all of which incre…”
BackgroundEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Athyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Kelley, D. E., McKolanis, T. M., Hegazi, R. A. F., Kuller, L. H., & Kalhan, S. C. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00117.2003 · Cited by 426
Speliotes, E. K., Butler, J. L., Palmer, C. D., Voight, B. F., & Hirschhorn, J. N. (2010) · Hepatology · doi:10.1002/hep.23768 · Cited by 362 · cited 1×
“However, the aforementioned I148M SNP of PNPLA3 was not associated with T2DM, despite being a genetic determinant of NAFLD severity.(56) In the above-mentioned meta-analysis (analysis of 6 studies),(23) I148M SNP was not significantly associated with the homeostatic model of assessment insulin resistance (HOMA-IR).”
BackgroundEpidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)
Bellentani, S., & Marino, M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31820-4 · Cited by 322
Colagiuri, S., Cull, C. A., Holman, R. R., & For the UKPDS Group (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1410 · Cited by 183 · cited 2×
“Finally, considering the T2DM paradigm, early treatment initiation for T2DM, at a time when the HbA1c is not significantly elevated, is associated with improved glycemic control over time and decreased long-term complications.(45) Prompt treatment initiation in NAFLD patients, similar to T2DM patients, might be more e…”
Method
Research works printed but not linked: 64
- Sanyal, 2011, NASH: a global health problem., Hepatol Res, 41, 670, 10.1111/j.1872-034X.2011.00824.x · DOI · Paper page
- Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults., Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x · DOI · Paper page
- Hamaguchi, 2005, The metabolic syndrome as a predictor of nonalcoholic fatty liver disease., Ann Intern Med, 143, 722, 10.7326/0003-4819-143-10-200511150-00009 · DOI · Paper page
- Whalley, 2007, Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs., Clin Med, 7, 119, 10.7861/clinmedicine.7-2-119 · DOI · Paper page
- Suzuki, 2005, Chronological development of elevated aminotransferases in a nonalcoholic population., Hepatology, 41, 64, 10.1002/hep.20543 · DOI · Paper page
- Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study., Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 · DOI · Paper page
- Chitturi, 2011, Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground., J Gastroenterol Hepatol, 26, 163, 10.1111/j.1440-1746.2010.06548.x · DOI · Paper page
- Polyzos, 2009, Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines., Curr Mol Med, 72, 299, 10.2174/156652409787847191 · DOI · Paper page
- Musso, 2011, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity., Ann Med, 43, 617, 10.3109/07853890.2010.518623 · DOI · Paper page
- Younossi, 2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality., Hepatology, 53, 1874, 10.1002/hep.24268 · DOI · Paper page
- Calori, 2011, Fatty liver index (FLI) and mortality: the cremona study at the 15(th) year of follow up., Hepatology, 54, 145, 10.1002/hep.24356 · DOI · Paper page
- Ertle, 2011, Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis., Int J Cancer, 128, 2436, 10.1002/ijc.25797 · DOI · Paper page
- Ong, 2008, Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease., J Hepatol, 49, 608, 10.1016/j.jhep.2008.06.018 · DOI · Paper page
- Polyzos, 2009, The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease., Hippokratia, 13, 127
- Krawczyk, 2010, Nonalcoholic fatty liver disease., Best Pract Res Clin Gastroenterol, 24, 695, 10.1016/j.bpg.2010.08.005 · DOI · Paper page
- Daly, 2011, Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease., Expert Rev Gastroenterol Hepatol, 5, 253, 10.1586/egh.11.18 · DOI
- Chalasani, 2010, Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease., Gastroenterology, 139, 1567, 10.1053/j.gastro.2010.07.057 · DOI · Paper page
- Sookoian, 2011, Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease., Hepatology, 53, 1883, 10.1002/hep.24283 · DOI · Paper page
- Lonardo, 2011, Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of multiorganelle failure Proceedings of a virtual workshop on nonalcoholic steatohepatitis., Expert Rev Gastroenterol Hepatol, 5, 135, 10.1586/egh.11.24 · doi:10.1586/egh.11.24
- Tilg, 2010, Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation., Curr Opin Clin Nutr Metab Care, 13, 391, 10.1097/MCO.0b013e32833a87cc · DOI
- Zhan, 2010, Roles of liver innate immune cells in nonalcoholic fatty liver disease., World J Gastroenterol, 16, 4652, 10.3748/wjg.v16.i37.4652 · DOI · Paper page
- Ratziu, 2010, A position statement on NAFLDNASH based on the EASL 2009 special conference., J Hepatol, 53, 372, 10.1016/j.jhep.2010.04.008 · DOI · Paper page
- Nseir, 2011, Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease., Dig Dis Sci, 56, 3439, 10.1007/s10620-011-1767-y · DOI
- Valenti, 2010, Homozygosity for the patatin-like phospholipase-3adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease., Hepatology, 51, 1209, 10.1002/hep.23622 · DOI · Paper page
- Valenti, 2011, Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C., Hepatology, 53, 791, 10.1002/hep.24123 · DOI · Paper page
- Greenberg, 2011, The role of lipid droplets in metabolic disease in rodents and humans., J Clin Invest, 121, 2102, 10.1172/JCI46069 · DOI · Paper page
- Samuel, 2011, Fructose induced lipogenesis: from sugar to fat to insulin resistance., Trends Endocrinol Metab, 22, 60, 10.1016/j.tem.2010.10.003 · DOI · Paper page
- Lombardi, 1968, Choline-deficiency fatty liver: impaired release of hepatic triglycerides., J Lipid Res, 9, 437, 10.1016/S0022-2275(20)42721-X · DOI
- Koek, 2011, The role of oxidative stress in non-alcoholic steatohepatitis., Clin Chim Acta, 412, 1297, 10.1016/j.cca.2011.04.013 · DOI · Paper page
- Dara, 2011, The contribution of endoplasmic reticulum stress to liver diseases., Hepatology, 53, 1752, 10.1002/hep.24279 · DOI · Paper page
- Serviddio, 2011, Mitochondrial dysfunction in nonalcoholic steatohepatitis., Expert Rev Gastroenterol Hepatol, 5, 233, 10.1586/egh.11.11 · DOI
- Targher, 2007, Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients., Diabetes Care, 30, 1212, 10.2337/dc06-2247 · DOI · Paper page
- Prashanth, 2009, Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus., J Assoc Physicians India, 57, 205
- Williamson, 2011, Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study., Diabetes Care, 34, 1139, 10.2337/dc10-2229 · DOI · Paper page
- Leite, 2011, Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors., Liver Int, 31, 700, 10.1111/j.1478-3231.2011.02482.x · DOI · Paper page
- Smith, 2011, Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment., Nat Rev Endocrinol, 7, 456, 10.1038/nrendo.2011.72 · DOI · Paper page
- Manchanayake, 2011, Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease., J Gastroenterol Hepatol, 26, 510, 10.1111/j.1440-1746.2010.06528.x · DOI · Paper page
- Carvalho, 2011, The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis., Ann Med, 43, 487, 10.3109/07853890.2011.554428 · DOI
- Musso, 2010, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease., Hepatology, 52, 79, 10.1002/hep.23623 · DOI · Paper page
- Dowman, 2011, Current therapeutic strategies in non-alcoholic fatty liver disease., Diabetes Obes Metab, 13, 692, 10.1111/j.1463-1326.2011.01403.x · DOI · Paper page
- Kaser, 2010, Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease., Int J Clin Pract, 64, 968, 10.1111/j.1742-1241.2009.02327.x · DOI
- Wang, 2011, The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population., Liver Int, 31, 1326, 10.1111/j.1478-3231.2011.02526.x · DOI
- Petit, 2011, PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes., Liver Int, 31, 1332, 10.1111/j.1478-3231.2011.02566.x · DOI
- Cox, 2011, Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus., Diabetes Metab, 37, 452, 10.1016/j.diabet.2011.05.001 · doi:10.1016/j.diabet.2011.05.001
- Sanyal, 2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis., Hepatology, 54, 344, 10.1002/hep.24376 · DOI · Paper page
- Loria, 2010, Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee., Dig Liver Dis, 42, 272, 10.1016/j.dld.2010.01.021 · DOI · Paper page
- Lutchman, 2007, The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis., Hepatology, 46, 424, 10.1002/hep.21661 · DOI · Paper page
- Nissen, 2010, Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality., Arch Intern Med, 170, 1191, 10.1001/archinternmed.2010.207 · DOI · Paper page
- Harrison, 2003, Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis., Am J Gastroenterol, 98, 2485, 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- Athyros, 2006, Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study., Curr Med Res Opin, 22, 873, 10.1185/030079906X104696 · DOI · Paper page
- Filippatos, 2010, Combination drug treatment in patients with non-alcoholic fatty liver disease., World J Hepatol, 2, 139, 10.4254/wjh.v2.i4.139 · DOI
- Voican, 2011, Insulin resistance and oxidative stress: two therapeutic targets in non-alcoholic steatohepatitis., J Hepatol, 54, 388, 10.1016/j.jhep.2010.07.054 · DOI
- Abel, 2009, Safety and efficacy of combined ezetimibesimvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease., Med Sci Monit, 15, 6
- Dufour, 2006, Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis., Clin Gastroenterol Hepatol, 4, 1537, 10.1016/j.cgh.2006.09.025 · DOI · Paper page
- Balmer, 2009, Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis., Liver Int, 29, 1184, 10.1111/j.1478-3231.2009.02037.x · DOI · Paper page
- Ersoz, 2005, Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment., Turk J Gastroenterol, 16, 124
- Foster, 2011, Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial., Am J Gastroenterol, 106, 71, 10.1038/ajg.2010.299 · DOI · Paper page
- Loguercio, 2007, The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: a pilot study., Dig Dis Sci, 52, 2387, 10.1007/s10620-006-9703-2 · DOI
- Nobili, 2006, Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease., Aliment Pharmacol Ther, 24, 1553, 10.1111/j.1365-2036.2006.03161.x · DOI · Paper page
- Nobili, 2008, Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial., Hepatology, 48, 119, 10.1002/hep.22336 · DOI · Paper page
- Omer, 2010, Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease., Eur J Gastroenterol Hepatol, 22, 18, 10.1097/MEG.0b013e32832e2baf · DOI · Paper page
- Polyzos, 2011, Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease., J Renin Angiotensin Aldosterone Syst, 12, 498, 10.1177/1470320311402110 · DOI
- Sanyal, 2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis., Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4 · DOI · Paper page
- Yokohama, 2004, Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis., Hepatology, 40, 1222, 10.1002/hep.20420 · DOI · Paper page
Cited by
Jung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
Self-citationAdipokines in nonalcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2015.11.006 · Cited by 348
Self-citationLeptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235
Self-citationLee, Y.-S., Kim, S. Y., Ko, E., Lee, J.-H., Yi, H.-S., Yoo, Y. J., Je, J., Suh, S. J., Jung, Y. K., Kim, J. H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03389-2 · Cited by 233
Metadata
- Authors
- Polyzos, S. A., Kountouras, J., Zavos, C., & Deretzi, G.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2012-04
- Volume
- 46
- Issue
- 4
- Pages
- 272-284
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2047189101
- Cited by
- 152
- References
- 14
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. https://app.cochat.ai/papers/10.1097/mcg.0b013e31824587e0
- The paper
- Polyzos, S. A., Kountouras, J., Zavos, C., & Deretzi, G. (2012). Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0b013e31824587e0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.